Delineating minimal protein domains and promoter elements for transcriptional activation by lentivirus Tat proteins by Southgate, Christopher D. & Green, Michael R.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
1995-04-01 
Delineating minimal protein domains and promoter elements for 
transcriptional activation by lentivirus Tat proteins 
Christopher D. Southgate 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Repository Citation 
Southgate CD, Green MR. (1995). Delineating minimal protein domains and promoter elements for 
transcriptional activation by lentivirus Tat proteins. Open Access Articles. Retrieved from 
https://escholarship.umassmed.edu/oapubs/1550 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
JOURNAL OF VIROLOGY, Apr. 1995, p. 2605–2610 Vol. 69, No. 4
0022-538X/95/$04.0010
Copyright q 1995, American Society for Microbiology
Delineating Minimal Protein Domains and Promoter Elements
for Transcriptional Activation by Lentivirus Tat Proteins
CHRISTOPHER D. SOUTHGATE† AND MICHAEL R. GREEN*
Howard Hughes Medical Institute, Program in Molecular Medicine, University of
Massachusetts Medical Center, Worcester, Massachusetts 01605
Received 21 October 1994/Accepted 19 December 1994
Lentivirus Tat proteins comprise a novel class of RNA-binding transcriptional activators that are essential
for viral replication. In this study, we performed a series of protein fusion experiments to delineate the minimal
protein domains and promoter elements required for Tat action. We show that a 15-amino-acid region of
equine infectious anemia virus (EIAV) Tat protein, when fused to the GAL4 or LexA DNA binding domain, can
activate transcription in appropriate promoter contexts. In the natural human immunodeficiency virus type 1
long terminal repeat, activation by Tat is dependent on multiple binding sites for the cellular transcription
factor SP1. We delineate a 114-amino-acid region of the SP1 glutamine-rich activation domain that when fused
to the GAL4 DNA binding domain can support transcription activation by Tat. Using these Tat and SP1
derivatives, we show that Tat activation can be reconstructed on a completely synthetic promoter lacking all
cis-acting elements unique to the human immunodeficiency virus long terminal repeat. Our results indicate
that lentivirus Tat proteins have essential properties of typical cellular transcriptional activators and define
useful reagents for studying the detailed mechanism of Tat action.
Human immunodeficiency virus (HIV), simian and bovine
immunodeficiency viruses (6, 26), and equine infectious ane-
mia virus (EIAV) (9) are lentiviruses that encode a novel class
of transcription activators termed Tat proteins. Tat proteins
differ from any known cellular activator in that they are tar-
geted to and activate transcription from nascent RNA.
Typical cellular transcriptional activators are composed of
two separable functional domains: the transcription effector or
activation domain, and a promoter-targeting domain that di-
rects the transcriptional activation region to the promoter (27).
The results of protein fusion experiments (31, 33) have shown
that Tat also contains two separable functional domains: an
arginine-rich RNA binding domain that targets Tat to nascent
TAR RNA, and a transcriptional activating region. For exam-
ple, HIV type 1 (HIV-1) Tat sequences have been fused to
either RNA (Rev [21] or R17 [31]) or DNA (GAL4 [16, 33])
binding domains. These chimeric Tat proteins activate tran-
scription efficiently when targeted artificially to their appropri-
ate RNA or DNA binding sites within the vicinity of the pro-
moter.
The HIV-1 long terminal repeat (LTR) is an extremely com-
plex regulatory element that contains binding sites for a variety
of cellular transcription factors, including: NF-kB/rel (24), SP1
(14), ets (32),myb (7), USF (10), GATA-3 (36), YY1 (22), LBP
(37). We have taken a long-term strategy to delineate the
minimal protein sequences and promoter elements essential
for transcription activation by Tat. In this report, we describe
minimal Tat derivatives, SP1 derivatives, and promoters that
support Tat responsiveness.
Recent studies have shown that a Tat-R17 chimeric protein,
containing a 15-amino-acid core domain of the distantly re-
lated EIAV Tat protein, can activate transcription from nas-
cent RNA (8). To determine whether the core region of EIAV
Tat (8) can also function when bound to the promoter, the
15-amino-acid EIAV Tat core region was fused in frame to
GAL4(1-95), which contains the DNA binding and dimeriza-
tion domains of the yeast activator GAL4. The resulting
GAL4-ETat expression plasmid was cotransfected into HeLa
cells with the reporter G6 280/184 HIV LTR. Figure 1A
(lanes 2 and 4) shows that GAL4(1-95)–ETat activates tran-
scription as efficiently as GAL4-HTDC, which contains the
HIV-1 Tat activation domain (residues 1 to 49) fused to
GAL4(1-95). Note that GAL4-HTDC lacks the Tat RNA bind-
ing domain and thus cannot work through the TAR RNA
element.
The central Phe residue within the 15-amino-acid core re-
gion of EIAV Tat is conserved among all known lentivirus Tat
proteins (4). We therefore introduced a Phe3Ala mutation
into each of these GAL4-Tat derivatives. Figure 1A shows that
this single amino acid mutation abolished transcription activa-
tion by GAL4-ETat, GAL4-HTDC, and HIV-1 Tat. We con-
clude that the 15-amino-acid core region of EIAV Tat can
function efficiently when bound to HIV-1 LTR promoter DNA
in human cells and that the highly conserved central Phe res-
idue within this core region is critical for activity.
The activation domain of HIV-1 Tat resides within its ami-
no-terminal 47 amino acids and consists of an acidic amino
terminal domain, a Cys-rich domain, and the conserved core
region (18, 28, 30). Substitutions within any of these domains
can abolish function of wild-type Tat as well as Tat derivatives
that act by targeting nascent RNA (31) or upstream promoter
DNA (33). Figure 1B shows the ability of the minimal core
region of HIV-1 Tat to activate transcription when targeted to
upstream promoter DNA. The 15-amino-acid core regions of
HIV-1 Tat and EIAV Tat were first fused in frame to the
full-length bacterial repressor protein LexA(1-202) and sub-
cloned into a mammalian expression vector. The LexA deriv-
atives were cotransfected into HeLa cells together with an L6
(283) HIV LTR DTAR reporter (Fig. 1B). Whereas the
LexA-ETat derivative activated transcription, the Lex-HTat
core derivative was inactive (compare lanes 2 and 4). Once
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again, the Phe3Ala mutation within the core region of LexA-
ETat (Lex-ETat Phe) abolished activity (lane 3). These com-
bined data indicate that the core region of HIV-1 Tat is unable
to activate transcription when tethered to upstream HIV-1
LTR promoter DNA under conditions in which the core ele-
ment of EIAV Tat functions efficiently.
We have previously shown that HIV-1 Tat activates tran-
scription from the HIV-1 LTR by cooperating with promoter-
proximal cellular transcription factors, in particular SP1 (3,
33): a GAL4-SP1 derivative, containing the activation region A
of SP1 fused to GAL4(1-147), cooperated with RNA-bound
HIV-1 Tat to stimulate transcription greater than 80-fold (33).
Activation region A of SP1 contains both a Ser/Thr-rich region
FIG. 2. Lex-Tat and GAL4-SP1 derivatives cooperate to activate transcrip-
tion. (A) The 114-amino-acid glutamine-rich region A of SP1 can support Tat-
mediated transcriptional activation. Deletion mutants of SP1 region A contain-
ing the Ser/Thr- and glutamine-rich regions (GLN) or only a 60-amino-acid
subdomain of the GLN region were fused to GAL4 residues 1 to 95 and cloned
into a cytomegalovirus-driven expression vector as indicated. L6G1 (231) HIV-1
LTR was constructed by cloning six LexA sites upstream of the previously
described G1 (231) HIV-1 LTR reporter (31). The LexA, Lex-ET, and HIV-1
Tat expression plasmids and the L6G1 (231) HIV LTR reporter were cotrans-
fected into HeLa cells in the presence of expression plasmids indicated above the
lanes by using the calcium phosphate coprecipitation technique. (B) Sequences
downstream of the transcription start site are not required for activation by
Lex-Tat. Six LexA sites and one GAL4 site were cloned upstream of HIV LTR
positions231 to11 as shown. This reporter was then transfected into HeLa cells
with various combinations of the LexA and GAL4 derivatives as described for
panel A. CAT activity was determined 48 h posttransfection. (C) Schematic
diagram of reporters and activators.
FIG. 1. Transcription activation by HIV-1 and EIAV Tat fusion proteins. (A) The CAT assay is shown above, and a schematic diagram of the reporter and activator
proteins is shown below. GAL4-ETat contains the 15-amino-acid ETat core region (8) fused to GAL4(1-95), which contains the DNA binding and dimerization domains
of the yeast activator protein GAL4. The G6 (283) HIV-1 LTR reporter was constructed by cloning five GAL4 17-mer DNA binding sites upstream of the previously
described G1 (283) HIV LTR reporter (33). GAL4(1-95) sequences were first cloned into the PECMV NH vector, a mammalian expression plasmid identical to the
previously described PECE except that the simian virus 40 early promoter was replaced with cytomegalovirus (CMV) immediate-early promoter and the plasmid
backbone is pSP72 (Promega). By using PCR technology, all EIAV Tat and HIV-1 Tat sequences and mutants were cloned in frame into the PECMV-GAL4(1-95)
expression plasmid and sequenced. This reporter was then cotransfected into HeLa cells in the presence of either GAL4(1-95), CMV-HTat, CMV GAL4-HTDC, or
GAL4-ET, using the calcium phosphate coprecipitation technique (33). At 48 to 72 h after transfection, the cells were harvested and CAT activity was measured.
GAL4-ETat and GAL4-HTDC Phe38 mutants contain the previously described Phe3Ala mutation within the HTat or ETat core domain as indicated in panel B. (B)
The CAT assay is shown above, and a schematic diagram of the reporter and activator proteins is shown below. The DNA sequences encoding the core region of either
EIAV Tat or HIV-1 Tat, depicted in the diagram, were fused in frame to the bacterial protein LexA(1-202), giving rise to Lex-ETat or Lex-HT, respectively. The
Phe3Ala mutation was introduced into the EIAV Tat core region as shown. We constructed a L6 (283) HIV LTR DTAR reporter in which the GAL4 sites in the
previously described G6 (283) HIV-1 LTR DTAR construct (31) were replaced by six LexA operator DNA binding sites obtained from the previously described
L6E1bCAT reporter (23). LexA(1-202), Lex-ETat, Lex-ETat Phe, and Lex-HT expression plasmids were individually cotransfected with the L6 (283) HIV LTR DTAR
reporter into HeLa cells by the calcium phosphate coprecipitation technique. After 48 to 72 h, the cells were harvested and CAT activity was measured.
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and a Gln-rich region (15). To determine the contribution of
these two motifs in Tat activation, we constructed GAL4-SP1
derivatives containing the glutamine-rich domain A alone de-
leted of the Ser/Thr-rich domain (GAL4-SP1 GLN) or a por-
tion of the Gln-rich subdomain (GAL4-SP1 GLND) (Fig. 2A).
These derivatives were then cotransfected with Lex, Lex-ETat,
Lex-ETat Phe (containing the Phe3Ala mutation), or the
HIV-1 Tat expression plasmids and either of two reporter
plasmids, L6 G1 HIV LTR chloramphenicol acetyltransferase
(CAT) (containing six Lex sites, one GAL4 site, and HIV LTR
sequences between 231 and 184) or L6 G1 HIVin CAT (con-
taining six Lex sites, one GAL4 site, and HIV LTR sequences
between 231 and 11) (Fig. 2C). As shown in Fig. 2A, a
144-amino-acid glutamine-rich fragment lacking the Ser/Thr-
rich domain efficiently supported activation by Lex-ETat or
HIV-1 Tat. Further deletion into the glutamine-rich region
(GAL4-SP1 GLND) eliminated Tat responsiveness.
Figure 2B shows that similar results were obtained with the
L6 G1 HIVin CAT reporter: once again, the 114-amino-acid
fragment of the SP1 glutamine-rich region A supported acti-
vation by LexA-ETat. Furthermore, these results show that
sequences downstream of position 11 are dispensable for ac-
tivation by LexA-ETat.
We next directly compared the abilities of EIAV and HIV-1
Tat activation domains to cooperate with the 114-amino-acid
glutamine-rich activation domain of SP1. Figure 3A shows that
GAL4-SP1 GLN, Lex-ETat core, and Lex-HTDC by them-
selves failed to activate transcription significantly. However,
Lex-ETat or Lex-HTDC together with GAL4-SP1 GLN acti-
vated transcription in a cooperative fashion to comparable
levels. Mutation of the Phe residue within the core region of
these Lex-Tat derivatives severely impaired activity. We con-
clude that the 15-amino-acid core region of ETat and the
47-amino-acid activation region of HIV-1 Tat can cooperate
with the 114-amino-acid glutamine-rich region of SP1 with
similar efficiencies and that this activity requires the conserved
Phe residue within the Tat core.
Several reports have suggested that sequences surrounding
the HIV-1 LTR TATA element as well as the transcription
initiation site and leader region may be involved in transcrip-
tional regulation (29). To define further the role of HIV-1
LTR cis-acting sequences in Tat function, the GAL4-SP1
GLN, Lex-ETat, and Lex-HTDC derivatives were cotrans-
fected into HeLa cells together with a reporter, L6 G1 E1b
CAT, that contains six LexA operator sites inserted upstream
of the GAL4 site in the previously described synthetic
G1E1bCAT reporter (20). Thus, this synthetic promoter lacks
any natural HIV LTR sequences and contains no promoter
element unique to the HIV LTR. Figure 3B shows that on L6
G1 E1b CAT, both Lex-ETat and Lex-HTDC can cooperate
with GAL4-SP1 GLN to activate transcription. We conclude
that no cis-acting sequence unique to the HIV-1 LTR is es-
sential for activation by Lex-ETat.
FIG. 3. Lentivirus Tat derivatives activate transcription from simplified pro-
moters. (A) LexA-ETat and LexA-HTDC derivatives cooperate with the minimal
glutamine-rich activation domain A of SP1 to activate transcription. The indi-
cated combinations of LexA, LexA-ETat, LexA-ETat Phe, LexA-HTDC, and
LexA-HTDC Phe derivatives in the presence of either GAL4(1-96) or GAL4-SP1
GLN were cotransfected together with the L6 G1 (231) HIVin reporter into
HeLa cells. Cells were harvested 48 to 72 h after transfection and processed as
previously described. (B) Transcription activation from a completely synthetic
promoter. Six LexA sites were cloned upstream of the previously described
G1E1bCAT reporter (20). This L6 G1 E1b CAT reporter was then cotransfected
into HeLa cells together with the indicated combinations of LexA and GAL4
derivatives. Cells were harvested 48 to 72 h posttransfection, and CAT activity
was assayed. (C) Schematic diagram of reporters and activators.
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Tat activation of the HIV-1 LTR is severely impaired in
most rodent cell lines (2, 12, 25). This defect is rescued in
human-rodent hybrid cells harboring human chromosome 12
(2, 25). To gain insight into the nature of the defect in rodent
cells, the G6 (283) HIV LTR reporter was transfected into
CHO cells in the presence of either an HIV-1 Tat, GAL4-
ETat, or GAL4-HTDC expression plasmid. As expected from
previous studies, Fig. 4 shows that in CHO cells, HIV-1 Tat
activated transcription from the G6 (283) HIV LTR very
poorly (compare with Fig. 1A). In contrast, transcription was
activated by GAL4(1-147)–HTDC and to a lesser extent by
GAL4(1-95)–ET and GAL4(1-95)–HTDC (lanes 6, 2, and 4,
respectively). In all instances, the Phe residue within the core
region of these GAL4-Tat derivatives was critical for activity.
We conclude that in CHO cells, Tat can activate transcription
when bound to GAL4 DNA binding sites upstream of the
transcription initiation site but not when targeted through nas-
cent TAR RNA. The most likely interpretation of these re-
sults, and those of related studies (1, 21), is that in vivo the
Tat-TAR interaction requires a human factor that is absent (or
not functional) in CHO cells.
The results presented here and in previous protein fusion
studies indicate that lentivirus Tat proteins have the hallmarks
of typical transcription activators: they are modular (31, 33),
they can act from upstream promoter DNA (33), and their
activation regions cooperate with cellular transcription factors
such as SP1 (3, 33, 35). Even the ability to activate transcrip-
tion from nascent RNA is no longer unique to lentivirus Tat
proteins: the acidic activator VP16 can activate HIV-1 LTR-
directed transcription when tethered artificially to nascent
RNA (34).
Two models have been proposed to explain how HIV-1 Tat
activates transcription (5, 11, 13). First, the RNA enhancer
model posits that RNA-bound HIV-1 Tat interacts with the
upstream promoter to stimulate transcription initiation. Sec-
ond, the processivity model postulates that HIV-1 Tat interacts
with transcription complexes assembled at the HIV LTR pro-
moter to increase the processivity of RNA polymerase II (5, 11,
17, 19). If the HIV-1 LTR directed an unusually poorly pro-
cessive RNA polymerase II, one would expect to find a unique
promoter element that is specifically required for Tat function.
On the contrary, we show that Tat can activate transcription
from a totally synthetic promoter lacking all cis-acting ele-
ments unique to the HIV-1 LTR.
Transcription activation by Tat appears to involve a complex
series of protein-protein interactions between the activator
domains of SP1 and HIV-1 Tat, putative adaptor molecules,
and specific general transcription factors. The exact sequence
of events leading to Tat activation of transcription awaits de-
tailed analyses using Tat-responsive in vitro transcription sys-
tems. We anticipate that the minimal LexA-Tat and GAL4-
SP1 derivatives described here will facilitate such in vitro
mechanistic studies.
We thank D. Derse for EIAV constructs and members of our lab-
oratory for critical comments on the manuscript.
FIG. 4. Transcription activation by GAL4-Tat derivatives in CHO cells. The G6 (283) HIV LTR reporter, depicted in Fig. 1A, was cotransfected into CHO cells
together with either GAL4(1-95), GAL4-ETat, GAL4-ETat Phe, GAL4-HTDC, GAL4-HTDC Phe, or GAL4(1-147)–HTDC derivatives by using the DEAE-dextran
technique (20). Cells were harvested 48 to 72 h posttransfection, and CAT activity was measured.
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